SPDR S&P Biotech ETF (XBI) shows strong bullish breakout with targets above $150.

The SPDR S&P Biotech ETF (XBI) has maintained a strong bullish trend since breaking out of a 44-month consolidation in October, reaching a high of $139.19 by April. After a brief pullback to key support near the 50-day moving average, XBI has resumed upward momentum, signaling potential gains toward $150 and possibly $165. This sustained strength reflects ongoing accumulation and a solid technical foundation for further growth in the biotech sector.